Go to Page # Page of 17

A New Medicine to Treat Inflammatory Diseases

 Thomas Jonassen, Jeppe Ovlesen
Description: AP1189 is a new medicine to treat inflammatory diseases. AP1189 is developed as an add-on to MTX to reduce inflammation and support resolution.
Views: 2111
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: SynAct Pharma AB
 ‐ More of their Presentations
weSRCH App on Apple
AP1189 - A new medicine to treat inflammatory
Thomas Jonassen, CSO

Jeppe Øvlesen, CEO

Sedermeradagen Malmø 2018

AP1189 – a melanocortin receptor agonist to reduce inflammation and “boost” healing
➔ First indication: active inflammatory joint diseases (rheumatoid and psoriatic arthritis)
➔ Opportunity: additional indications b ... See more

Recent Presentations

Laura Collie PhD
17 June, 2019
Shuyang Zhang MD
14 June, 2019

Pharmaceutical Track and Trace System (ITS)

Trace System and its works for following and pursue all medication in store system of Turkey. Framework covers every solution confine all methods for stock system, from age/import

13 June, 2019